Vical to present results of Vaxfectin adjuvant at Conference in Hungary

Download PDF Copy

Nov 20 2010

NewsGuard 100/100 Score

Vical Incorporated (Nasdaq:VICL) today announced that the company is presenting an overview of results for its patented Vaxfectin^® adjuvant at the Modern Veterinary Vaccines & Adjuvants conference (Budapest, Hungary, November 17 – 19).

Vaxfectin^® has demonstrated promising results in a broad range of animal studies in infectious disease and cancer vaccine applications including DNA, protein and peptide vaccines, as well as initial human studies with pandemic influenza DNA vaccines. The company is exploring international partnering opportunities for veterinary applications of its technologies to supplement its existing pipeline of independent and collaborative programs.

Source: Vical Incorporated

Posted in: Medical Condition News | Disease/Infection News | Pharmaceutical News

Tags: Biotechnology, Cancer, DNA, G-Protein, Infectious Diseases, Influenza, Pandemic, Peptides, Protein, Vaccine, Veterinary

Comments (0)

Download PDF Copy

Suggested Reading

DNA barcoding reveals hidden species diversity

DNA barcoding reveals hidden species diversity

Radioprotective effects of Licochalcone B against radiation-induced cell damage

Radioprotective effects of Licochalcone B against radiation-induced cell damage

Persistent activation of DNA damage response in the liver after MASLD reversal

Persistent activation of DNA damage response in the liver after MASLD reversal

Breakthrough research reveals how to target malignant DNA in aggressive cancers

Breakthrough research reveals how to target malignant DNA in aggressive cancers

Epigenetic silencing of BEND4 unveils new path for PDAC treatment

Epigenetic silencing of BEND4 unveils new path for PDAC treatment

MethylGPT unlocks DNA secrets for age and disease prediction

MethylGPT unlocks DNA secrets for age and disease prediction

Stanford researchers unveil the key role of extrachromosomal DNA in cancer

Stanford researchers unveil the key role of extrachromosomal DNA in cancer

A novel synthetic lethal target for ATM inhibitors in pancreatic cancer

A novel synthetic lethal target for ATM inhibitors in pancreatic cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Revolutionary AI predicts aging and disease from DNA patterns